Psilocybin vs. ketamine therapy is one of the most common questions people ask when exploring psychedelic-assisted approaches to mental health. Both have shown real clinical promise, particularly for treatment-resistant depression, but they work through different...
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single guided dose can produce meaningful, lasting reductions in PTSD symptoms. The evidence is promising, but also...
Last Updated: May 2026 Psychedelic therapy in California is a complicated picture in 2026. Ketamine is the one legally accessible option through licensed medical providers, while psilocybin remains a Schedule I substance under both state and federal law, despite local...
Set and setting psychedelics research refers to the two core non-pharmacological factors that shape a psilocybin experience: your internal state (set) and the physical and relational environment around you (setting). Both matter more than most first-timers expect, and...
The default mode network is a cluster of brain regions responsible for self-referential thinking, rumination, and your ongoing sense of “I.” Research on default mode network psychedelics shows that psilocybin temporarily disrupts this network’s rigid...
Psychedelic therapy for executives is moving beyond reputation and into clinical evidence. A growing number of C-suite leaders are using professionally supported psilocybin and ketamine experiences to address burnout, decision fatigue, and stalled thinking. Here is...
